Trypanosoma cruzi seroprevalence and associated risk factors in cancer patients from Southern Brazil.
The aim of this study was to investigate the prevalence of Chagas disease in patients treated at a Public Oncology Service in the City of Pelotas, Southern Brazil. This study included 200 individuals undergoing cancer treatment and involved the use of a questionnaire and venous blood collection for the detection of anti-Trypanosoma cruzi antibody. The study found a 5% prevalence of patient seropositivity. Significant variables are presented and discussed in the article. Serological T. cruzi checks are recommended in cancer patients, especially individuals from endemic areas in Brazil and other Latin American countries.